Purpose Several epidemiologic studies have evaluated the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and bladder cancer risk and the results were varied. Thus, we conducted a comprehensive meta-analysis of studies exclusively dedicated to the relationship between the 3 most commonly used analgesics and bladder cancer risk. Methods A systematic literature search up to November 2012 was performed in PubMed database for 3 categories of analgesics: acetaminophen, aspirin or non-aspirin NSAIDs. Study-specific risk estimates were pooled using a random-effects model. Results Seventeen studies (8 cohort and 9 case-control studies), involving a total of 10,618 bladder cancer cases, were contributed to the analysis. We found that acetaminophen (relative risk [RR] 1.01, 95% confidence interval [CI] 0.88–1.17) and aspirin (RR 1.02, 95% CI 0.91–1.14) were not associated with bladder cancer risk. Although non-aspirin NSAIDs was statistically significantly associated with reduced risk of bladder cancer among case-control studies (but not cohort studies), the overall risk was not statistically significant (RR 0.87, 95% CI 0.73–1.05). Furthermore, we also found that non-aspirin NSAIDs use was significantly associated with a 43% reduction in bladder cancer risk among nonsmokers (RR 0.57, 95% CI 0.43–0.76), but not among current smokers. Conclusion The results of our meta-analysis suggest that there is no association between use of acetaminophen, aspirin or non-aspirin NSAIDs and bladder cancer risk. However, non-aspirin NSAIDs use might be associated with a reduction in risk of bladder cancer for nonsmokers.
References
[1]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
[2]
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
[3]
Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030–3044.
[4]
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA (2004) The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21: 392–401.
[5]
Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M (2003) Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 57: 166–173.
[6]
Guo HR, Chiang HS, Hu H, Lipsitz SR, Monson RR (1997) Arsenic in drinking water and incidence of urinary cancers. Epidemiology 8: 545–550.
[7]
Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13: 559–583.
[8]
Luo T, Yan HM, He P, Luo Y, Yang YF, et al. (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131: 581–587.
[9]
Tian W, Zhao Y, Liu S, Li X (2010) Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 19: 288–298.
[10]
Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, et al. (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376–389.
[11]
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23: 1403–1415.
[12]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
[13]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
[14]
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[15]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for ystematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51: 264–269, W264.
[16]
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146.
[17]
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327.
[18]
Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99: 608–615.
[19]
Steineck G, Wiholm BE, Gerhardsson de Verdier M (1995) Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 34: 741–748.
[20]
Rosenberg L, Rao RS, Palmer JR, Strom BL, Zauber A, et al. (1998) Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 9: 83–88.
[21]
Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299: 1247–1250.
[22]
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320: 1642–1646.
[23]
Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313: 292–295.
[24]
Derby LE, Jick H (1996) Acetaminophen and renal and bladder cancer. Epidemiology 7: 358–362.
[25]
Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, et al. (1999) Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 14: 2892–2897.
[26]
Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364–1369.
[27]
Kaye JA, Myers MW, Jick H (2001) Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 12: 690–694.
[28]
Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, et al. (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97: 96–101.
[29]
Friis S, S？rensen HT, McLaughlin JK, Johnsen SP, Blot WJ, et al. (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88: 684–688.
[30]
S？rensen HT, Friis S, N？rg？rd B, Mellemkjaer L, Blot WJ, et al. (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88: 1687–1692.
[31]
Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, et al. (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24: 3177–3184.
[32]
Blumentals WA, Foulis PR, Schwartz SW, Mason TJ (2004) Analgesic therapy and the prevention of bladder cancer. Urol Oncol 22: 11–15.
[33]
Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardón A, et al. (2006) Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 15: 1696–1702.
[34]
Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, et al. (2007) Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 7: 13.
[35]
Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS (2007) Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 120: 2221–2225.
[36]
Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, et al. (2011) Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173: 721–730.
[37]
Jacobs EJ, Newton CC, Gapstur SM, Thun MJ (2012) Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 104: 1208–1217.
[38]
Shih C, Hotaling JM, Wright JL, White E (2012) Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study. Urol Oncol. [Epub ahead of print]
[39]
Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, et al. (2013) Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer 132: 162–173.
[40]
Clissold SP (1986) Paracetamol and phenacetin. Drugs 32: 46–59.
[41]
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, et al. (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294: 47–55.
[42]
Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002 21: 7435–7451.
[43]
Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS (2002) Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 20: 651–656.
